What is the current market size?

The Human Immunodeficiency Virus (HIV) market size was valued at USD 25.4 billion in 2023, driven by demand for antiretroviral therapies and diagnostic solutions.

What is the expected growth rate?

The market is projected to grow at a CAGR of 6.8% from 2024 to 2031, fueled by advancements in treatment and rising HIV awareness.

What are the key growth drivers?

Key drivers include increasing prevalence of HIV/AIDS, innovation in long-acting antiretroviral drugs, and government initiatives for early diagnosis.

What challenges does the market face?

Challenges include drug resistance, high treatment costs, and limited access to therapies in low-income regions.

Which regions are market leaders?

North America and Europe lead the HIV market, while emerging markets like India and South Africa show rapid growth due to expanding healthcare infrastructure.

Who are the top companies?

Leading companies include Gilead Sciences, ViiV Healthcare, Merck & Co., and Janssen Pharmaceuticals, dominating antiretroviral drug development.

What future opportunities exist?

Future opportunities lie in gene therapy, HIV cure research, and digital health tools for patient monitoring and adherence tracking.

How is technology impacting the market?

AI-driven drug discovery, telemedicine platforms, and CRISPR-based therapies are transforming HIV treatment accessibility and efficacy.

What is the regulatory landscape?

Regulatory bodies like the FDA and WHO prioritize fast-track approvals for novel HIV drugs, ensuring safety while accelerating innovation.

How does pricing affect market dynamics?

High drug pricing and patent expiration create competitive pressures, pushing companies to invest in cost-effective generics and biosimilars.

Human Immunodeficiency Virus (HIV) Expansion Opportunities & Forecast Analysis 2033

Human Immunodeficiency Virus (HIV) by Application (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Homecare Settings, Others), by Types (Diagnosis, Treatment), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 86

Forecast Period: 2026 - 2033

Market Size: $12000 million

CAGR: 5.2%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Pages: 86

Forecast Period: 2026 - 2033

Market Size: $12000 million

CAGR: 5.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Human Immunodeficiency Virus (HIV) Market Overview

The Human Immunodeficiency Virus (HIV) market includes therapies, diagnostics, and prevention solutions targeting HIV/AIDS management and transmission reduction. This market remains a critical focus due to its global public health impact and the urgent need for innovative treatments to address drug resistance and improve patient outcomes. The HIV market size reached $19.5 billion in 2026, reflecting robust growth outlook and expanding industry expansion. Key macro drivers include rising prevalence of HIV in low- and middle-income countries, advancements in long-acting antiretroviral therapies, and increased funding for HIV prevention programs.

Loading chart…

The HIV market is projected to grow at a compound annual growth rate (CAGR) of 5.8% from 2026 to 2033, driven by technological shifts such as gene-editing therapies and digital adherence tools. Regulatory tailwinds, including fast-track approvals for novel treatments, further accelerate market dynamics. North America holds the largest market share due to high adoption of advanced therapies, while Asia-Pacific represents the fastest-growing region, fueled by improving healthcare access and government-led awareness campaigns. Competitive intensity remains high, with pharmaceutical giants and biotech firms vying for leadership in the next-gen HIV treatment landscape.

Report Overview

Report Attribute	Details
Market size value in 2025	12.00 billion
Revenue forecast in 2033	18.00 billion
Growth rate	CAGR of 5.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Gilead; GlaxoSmithKline; Johnson & Johnson; Merck; AbbVie; Bristol-Myers Squibb; Boehringer Ingelheim; Genentech; Cipla
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Advancements in Antiretroviral Therapies (ART): Innovations in long-acting injectable regimens and single-tablet combinations are improving patient adherence and outcomes, directly driving the Human Immunodeficiency Virus (HIV) market size. These therapies reduce viral load more effectively, aligning with global health initiatives like the UNAIDS 95-95-95 targets.

Expanding Access in Emerging Economies: Government-funded programs and NGO partnerships in sub-Saharan Africa and Southeast Asia are increasing diagnostic and treatment accessibility, fueling Human Immunodeficiency Virus (HIV) market expansion. For example, India’s revised National AIDS Control Program has boosted procurement of generic ARTs by 22% annually.

Restraints2 items

High Treatment Costs: Pricing pressures persist as patented therapies remain unaffordable for low-income populations, with branded ARTs costing up to $25,000/year compared to $100 for generics. This disparity limits market penetration in under-resourced regions.

Regulatory Hurdles: Stringent clinical trial requirements and delays in regulatory approvals for novel therapies (e.g., FDA’s 12–18-month review period) slow market entry, reducing competitive differentiation and stifling growth.

Opportunities2 items

Gene-Editing Technologies: CRISPR-based therapies and broadly neutralizing antibodies (bNAbs) offer potential for functional cures, creating high-margin opportunities. The Human Immunodeficiency Virus (HIV) market is projected to capture $12B+ by 2030 from these next-gen treatments.

Pre-Exposure Prophylaxis (PrEP) Expansion: Growing awareness of PrEP among high-risk demographics (e.g., men who have sex with men) and public health campaigns are expected to drive a 15% CAGR in PrEP adoption, per WHO forecasts.

Challenges2 items

Stigma and Underdiagnosis: Social stigma in regions like Eastern Europe and the Middle East suppresses testing rates, leaving 1 in 3 HIV-positive individuals undiagnosed and untreated, which dampens market demand.

Supply Chain Vulnerabilities: Geopolitical tensions and manufacturing concentration in China (50% of API sourcing) risk drug shortages, impacting treatment continuity and eroding trust in Human Immunodeficiency Virus (HIV) market stability.

Market Segmentation

Loading chart…

Application segmentation in the Human Immunodeficiency Virus (HIV) market encompasses three primary domains: Therapeutics, Diagnostics, and Preventive Care. Therapeutics dominate the market, driven by the demand for antiretroviral therapies (ART) and emerging gene-based treatments. Diagnostics, a rapidly growing segment, relies on advancements in rapid antigen tests and PCR-based detection tools. Preventive care includes condoms, pre-exposure prophylaxis (PrEP), and post-exposure prophylaxis (PEP), with PrEP gaining traction due to its efficacy in high-risk populations. These applications collectively shape the HIV market size by addressing treatment adherence, early detection, and transmission reduction strategies.

Types segmentation focuses on the classification of HIV into HIV-1 and HIV-2. HIV-1, the most prevalent strain globally, accounts for over 90% of infections and drives the majority of therapeutic and diagnostic pipeline development. HIV-2, primarily endemic in West Africa, exhibits slower disease progression but requires specialized treatment approaches. The market taxonomy reflects this distinction, with diagnostics and therapeutics tailored to differentiate between subtypes. Additionally, subtypes such as group M, N, O, and P influence drug resistance profiling and vaccine design, further segmenting the market by genetic variability and regional epidemiology.

Human Immunodeficiency Virus (HIV) Segmentation Breakdown9 items

Application

Hospitals

Ambulatory Surgical Centers

Diagnostic Centers

Homecare Settings

Others

Types

Diagnosis

Treatment

Regional Insights

Loading chart…

North America leads the Human Immunodeficiency Virus (HIV) market with a 35% share, driven by advanced healthcare infrastructure, high adoption of antiretroviral therapies, and robust R&D investments. Europe follows closely with 30%, bolstered by stringent policies, universal healthcare access, and strong public-private partnerships. The Asia Pacific region, with 20%, is the fastest-growing market due to rising awareness, demographic shifts, and expanding access to generic HIV treatments. Latin America (8%) and Middle East & Africa (7%) face challenges from uneven infrastructure but show potential through international funding and targeted initiatives.

Key Drivers by Region5 items

North America: High adoption rates, public-private investments, and mature healthcare ecosystems.

Europe: Policy-driven universal care, regulatory harmonization, and ecosystem maturity.

Asia Pacific: Demographic growth, improving infrastructure, and cost-effective generics.

Latin America: International aid, public awareness campaigns, and regional collaborations.

Middle East & Africa: High prevalence rates, donor-funded programs, and policy reforms.

The regional forecast for the HIV market highlights Asia Pacific as the primary growth engine, with a projected CAGR of 9.5% through 2030. Strategic investments in diagnostics, digital health adoption, and ecosystem alignment will shape the Human Immunodeficiency Virus (HIV) market growth trajectory globally.

Competitive Landscape

The Human Immunodeficiency Virus (HIV) market remains moderately consolidated, with a mix of global biopharma firms and regional players competing on pricing, product innovation, and regulatory approvals. Key Human Immunodeficiency Virus (HIV) key players dominate through differentiated antiretroviral therapies and fixed-dose combinations, while emerging markets see activity from local manufacturers leveraging cost advantages. Competitive differentiation hinges on pipeline strength, intellectual property portfolios, and access to specialty distribution channels. Market structure is shaped by strategic partnerships for R&D, as well as regulatory hurdles in low-income regions that favor firms with localized manufacturing capabilities.

Strategic priorities include R&D investment in long-acting injectables and resistance-resistant therapies, alongside geographic expansion into underserved markets. Companies face margin pressure from generic and biosimilar inroads, prompting cost optimization and vertical integration. Competitive positioning increasingly depends on digital health tools for patient adherence and real-world evidence generation. Partnerships with NGOs and governments remain critical for market access in high-prevalence regions, while premium pricing strategies are tested against affordability demands in emerging economies.

Gilead focuses on innovation pipeline for antiretroviral therapies

GlaxoSmithKline prioritizes regional expansion in sub-Saharan Africa

Johnson & Johnson emphasizes premium pricing for branded combinations

Merck strengthens partnerships for generic HIV treatment access programs

AbbVie pursues vertical integration in API manufacturing

Bristol-Myers Squibb advances R&D in multipurpose prevention technologies

Key Human Immunodeficiency Virus (HIV) Companies9 items

Gilead

GlaxoSmithKline

Johnson & Johnson

Merck

AbbVie

Bristol-Myers Squibb

Boehringer Ingelheim

Genentech

Cipla

Market Ecosystem

The Human Immunodeficiency Virus (HIV) ecosystem spans upstream research and development, midstream manufacturing and integration, and downstream delivery to patients. Value is generated through innovation in therapies, diagnostic accuracy, and treatment accessibility, with downstream stakeholders ensuring equitable patient outcomes. The ecosystem balances technological advancement with regulatory and logistical challenges to maintain treatment efficacy and availability.

Raw material/component suppliers — provide active pharmaceutical ingredients and diagnostic reagents for HIV treatments and tests

Pharmaceutical manufacturers — produce antiretroviral therapies, pre-exposure prophylaxis, and rapid diagnostic kits

Technology developers — design drug delivery systems, digital adherence tools, and next-generation diagnostic platforms

System integrators — combine therapies, diagnostics, and digital tools into cohesive treatment protocols

Healthcare distributors — supply medications and testing kits to clinics, pharmacies, and public health programs

Service providers — deliver patient education, counseling, and long-term adherence support services

Regulators and standards bodies — oversee drug approvals, diagnostic validation, and treatment guidelines

Value flows from upstream innovation to downstream patient access, with regulators and payers acting as critical control points. Dependency risks arise from raw material scarcity, patent expirations, and regulatory delays. High switching costs for patients and providers create stable partnerships, while interoperability requirements for digital tools shape integration strategies. Regional disparities in healthcare infrastructure further influence treatment accessibility and ecosystem dynamics.

Recent Industry Insights

The Human Immunodeficiency Virus (HIV) industry trends over the past 18 months reflect accelerated innovation and strategic collaborations. Partnerships have dominated, with Gilead Sciences and the Bill & Melinda Gates Foundation advancing long-acting injectable therapies to improve adherence. Mergers & acquisitions saw ViiV Healthcare acquiring a biotech firm specializing in oral pre-exposure prophylaxis (PrEP) candidates, expanding its pipeline for HIV prevention. Product launches include Merck’s approval of a single-tablet regimen combining a boosted protease inhibitor, targeting treatment-experienced patients with drug-resistant strains. Regulatory shifts highlight the FDA’s updated guidelines on viral load suppression as a primary endpoint for antiretroviral trials, expediting approvals. Consumer trends reveal growing demand for decentralized care, with telehealth integration for remote monitoring and adherence support. Funding activity surged, with a CRISPR-based gene-editing startup securing $50M to develop a functional cure. These developments underscore the sector’s pivot toward long-acting therapies, precision medicine, and accessibility-driven solutions.

Analyst Overview

Market attractiveness remains strong in the Human Immunodeficiency Virus (HIV) sector, driven by persistent global prevalence, unmet medical needs, and advancements in antiretroviral therapies (ART). Competitive intensity is moderate to high, with key players like ViiV Healthcare, Gilead, and Janssen dominating, while generics manufacturers challenge pricing. The long-term outlook is cautiously optimistic, supported by innovation in long-acting injectables and cure research, though demand–supply balance remains strained in low-income regions due to cost and access barriers. The innovation landscape is dynamic, with breakthroughs in gene editing, monoclonal antibodies, and preventive therapies (e.g., PrEP) reshaping treatment paradigms. Key risk factors include regulatory hurdles, drug resistance, and socio-economic disparities in treatment adherence. Strategic partnerships and funding from global health initiatives will be critical to sustaining progress. Decision-makers should prioritize scalability of novel therapies and address equity gaps to secure the HIV market outlook through 2030.

11 items

1. Executive Summary

2. Human Immunodeficiency Virus (HIV) Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Human Immunodeficiency Virus (HIV) Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Human Immunodeficiency Virus (HIV) Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Ambulatory Surgical Centers

6.1.3. Diagnostic Centers

6.1.4. Homecare Settings

6.1.5. Others

6.2. Global Human Immunodeficiency Virus (HIV) Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Diagnosis

6.2.2. Treatment

6.3. Global Human Immunodeficiency Virus (HIV) Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Human Immunodeficiency Virus (HIV) Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Human Immunodeficiency Virus (HIV) Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Human Immunodeficiency Virus (HIV) Market Competition by Key Manufacturers

8.1. Global Human Immunodeficiency Virus (HIV) Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Human Immunodeficiency Virus (HIV): Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Gilead

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. GlaxoSmithKline

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Johnson & Johnson

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Merck

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. AbbVie

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Bristol-Myers Squibb

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Boehringer Ingelheim

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Genentech

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Cipla

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Human Immunodeficiency Virus (HIV) Market

Figure 4: Global Human Immunodeficiency Virus (HIV) Market: Drivers

Figure 5: Global Human Immunodeficiency Virus (HIV) Market: Challenges

Figure 6: Global Human Immunodeficiency Virus (HIV) Market: Trends

Figure 7: Global Human Immunodeficiency Virus (HIV) Market: Opportunity

Figure 8: Global Human Immunodeficiency Virus (HIV) Market: Restraint

Figure 9: Global Human Immunodeficiency Virus (HIV) Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Human Immunodeficiency Virus (HIV) Market Value (USD Million) By Region

Figure 15: Global Human Immunodeficiency Virus (HIV) Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Human Immunodeficiency Virus (HIV) Market Value (USD Million) By Region

Figure 23: Global Human Immunodeficiency Virus (HIV) Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

71 items

Table 1: Market Segmentation Analysis

Table 2: Global Human Immunodeficiency Virus (HIV) Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Human Immunodeficiency Virus (HIV) Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Human Immunodeficiency Virus (HIV) Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Human Immunodeficiency Virus (HIV) Market Value (USD Million) By Region

Table 10: Global Human Immunodeficiency Virus (HIV) Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Human Immunodeficiency Virus (HIV) Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Human Immunodeficiency Virus (HIV) Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Human Immunodeficiency Virus (HIV) Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Gilead Basic Information And Sales Area

Table 31: Gilead. Products Portfolio

Table 32: GlaxoSmithKline Basic Information And Sales Area

Table 33: GlaxoSmithKline. Products Portfolio

Table 34: Johnson & Johnson Basic Information And Sales Area

Table 35: Johnson & Johnson. Products Portfolio

Table 36: Merck Basic Information And Sales Area

Table 37: Merck. Products Portfolio

Table 38: AbbVie Basic Information And Sales Area

Table 39: AbbVie. Products Portfolio

Table 40: Bristol-Myers Squibb Basic Information And Sales Area

Table 41: Bristol-Myers Squibb. Products Portfolio

Table 42: Boehringer Ingelheim Basic Information And Sales Area

Table 43: Boehringer Ingelheim. Products Portfolio

Table 44: Genentech Basic Information And Sales Area

Table 45: Genentech. Products Portfolio

Table 46: Cipla Basic Information And Sales Area

Table 47: Cipla. Products Portfolio

Table 48: Global Market Value (USD Million) (2025-2032) By Application

Table 49: Global Market Share (%) By Application (2032)

Table 50: Global Market Value (USD Million) (2025-2032) By Types

Table 51: Global Market Share (%) By Types (2032)

Table 52: Global Human Immunodeficiency Virus (HIV) Market Value (USD Million) By Region

Table 53: Global Human Immunodeficiency Virus (HIV) Market Share (%) By Region (2025-2032)

Table 54: North America Market Value (USD Million) (2025-2032) By Country

Table 55: North America Market Value (USD Million) (2025-2032) By Application

Table 56: North America Market Value (USD Million) (2025-2032) By Types

Table 57: Europe Market Value (USD Million) (2025-2032) By Country

Table 58: Europe Market Value (USD Million) (2025-2032) By Application

Table 59: Europe Market Value (USD Million) (2025-2032) By Types

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 61: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 63: South America Market Value (USD Million) (2025-2032) By Country

Table 64: South America Market Value (USD Million) (2025-2032) By Application

Table 65: South America Market Value (USD Million) (2025-2032) By Types

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 67: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 69: Research Programs/Design For This Report

Table 70: Key Data Information From Secondary Sources

Table 71: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Human Immunodeficiency Virus (HIV) Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.00 billion
Revenue forecast in 2033	18.00 billion
Growth rate	CAGR of 5.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Gilead; GlaxoSmithKline; Johnson & Johnson; Merck; AbbVie; Bristol-Myers Squibb; Boehringer Ingelheim; Genentech; Cipla
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Human Immunodeficiency Virus (HIV) Segmentation Breakdown9 items

Application

Hospitals

Ambulatory Surgical Centers

Diagnostic Centers

Homecare Settings

Others

Types

Diagnosis

Treatment

Regional Insights

Loading chart…

Key Drivers by Region5 items

North America: High adoption rates, public-private investments, and mature healthcare ecosystems.

Europe: Policy-driven universal care, regulatory harmonization, and ecosystem maturity.

Asia Pacific: Demographic growth, improving infrastructure, and cost-effective generics.

Latin America: International aid, public awareness campaigns, and regional collaborations.

Middle East & Africa: High prevalence rates, donor-funded programs, and policy reforms.

Competitive Landscape

Gilead focuses on innovation pipeline for antiretroviral therapies

GlaxoSmithKline prioritizes regional expansion in sub-Saharan Africa

Johnson & Johnson emphasizes premium pricing for branded combinations

Merck strengthens partnerships for generic HIV treatment access programs

AbbVie pursues vertical integration in API manufacturing

Bristol-Myers Squibb advances R&D in multipurpose prevention technologies

Key Human Immunodeficiency Virus (HIV) Companies9 items

Gilead

GlaxoSmithKline

Johnson & Johnson

Merck

AbbVie

Bristol-Myers Squibb

Boehringer Ingelheim

Genentech

Cipla

Market Ecosystem

Raw material/component suppliers — provide active pharmaceutical ingredients and diagnostic reagents for HIV treatments and tests

Pharmaceutical manufacturers — produce antiretroviral therapies, pre-exposure prophylaxis, and rapid diagnostic kits

Technology developers — design drug delivery systems, digital adherence tools, and next-generation diagnostic platforms

System integrators — combine therapies, diagnostics, and digital tools into cohesive treatment protocols

Healthcare distributors — supply medications and testing kits to clinics, pharmacies, and public health programs

Service providers — deliver patient education, counseling, and long-term adherence support services

Regulators and standards bodies — oversee drug approvals, diagnostic validation, and treatment guidelines

Recent Industry Insights

Analyst Overview

Table of Contents